Dexpramipexole Targets Eosinophils to Reduce Plasma Cell Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for plasma cell disorders and B-cell disorders, such as multiple myeloma and lymphomas, face challenges in effectively reducing elevated plasma cell and B-cell levels due to drug resistance mechanisms and the supportive role of eosinophils and basophils in cell survival and proliferation.
Innovation Solution
Dexpramipexole, a synthetic aminobenzothiazole derivative, is administered therapeutically to decrease plasma cell and B-cell levels by targeting eosinophils and basophils, potentially overcoming cell adhesion-mediated drug resistance and promoting apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to reduce plasma cell and B-cell levels, then cell levels may be reduced, but drug resistance mechanisms develop and treatment effectiveness decreases
Solution Approach 1:
The patent extracts and targets the specific cellular mechanism (eosinophils and basophils) that supports plasma cell and B-cell survival. By removing this supportive element through dexpramipexole treatment, the patent addresses drug resistance by attacking the disease through a different pathway rather than directly targeting the resistant plasma cells themselves.
Solution Approach 2:
The patent uses dexpramipexole as an intermediary agent that indirectly reduces plasma cell and B-cell levels by targeting eosinophils and basophils. This intermediary approach bypasses direct drug resistance mechanisms that plasma cells may have developed against conventional therapies.
2Reliability
If conventional therapies are administered to decrease plasma cell levels, then cell proliferation may be inhibited, but adverse effects increase due to lack of selectivity
Solution Approach 1:
The patent applies local quality by targeting a specific cell type (eosinophils and basophils) with a specific drug mechanism (dexpramipexole) rather than using broad-spectrum immunosuppressants. This localized approach reduces adverse effects by sparing other healthy cell populations from unnecessary suppression.
Solution Approach 2:
The patent changes the therapeutic parameter from direct plasma cell targeting to eosinophil/basophil targeting. This parameter change allows for more selective treatment that reduces adverse effects while maintaining effectiveness in decreasing plasma cell and B-cell levels.
3Reliability
If treatment duration is extended to overcome drug resistance, then treatment effectiveness may improve, but treatment complexity and patient burden increase
Solution Approach 1:
Instead of extending treatment duration to overcome resistance, the patent inverts the approach by using a completely different mechanism of action (dexpramipexole targeting eosinophils/basophils) that may work more quickly and effectively, potentially shortening the treatment course required.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
Disclosed herein are methods of treating conditions, which may be associated with elevated levels of plasma cells and/or B-cells, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.